- Details
- Description
-
Packaging Size60t/bottle
-
Strength10mg
-
CompositonOlverembatinib
-
Formtablet
-
Brand耐立克
-
Quantity Unit10mg*60t/box
-
ManufacturerAscentage Pharma.,China
Olverembatinib is a small-molecule, oral BCR-ABL1 TKI that works by inhibiting the BCR-ABL1 kinase at the ATP binding site. It's designed to be effective against both wild-type and mutant BCR-ABL1.
- Olverembatinib sold under the brand name 耐立克® in china.
In 2021, it was approved in China "for the treatment of adult patients with TKI-resistant chronic-phase CML (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation"